On August 1, the list of "China's pharmaceutical innovation force in 2021" was unveiled at the 2021 (38th) National Pharmaceutical Industry Information Annual Conference. Dongfang Baitai won the list with its outstanding R&D strength and innovation spirit. A total of 12 well-known innovative enterprises were selected. It is the representative of the most innovative new force in China's pharmaceutical industry.

The list of new innovative forces of Chinese medicine was first launched in 2020. China Pharmaceutical Industry Information Center, the sponsor of the National Pharmaceutical Industry Information Annual Conference, together with China National Pharmaceutical Industry Research Institute and Shanghai Pharmaceutical Industry Research Institute, formed an expert selection team. Objective research and analysis of new and innovative enterprises in the pharmaceutical field in China based on the monitoring database of new drug R&D and the independent declaration data of enterprises. Each enterprise is scored in a multi-dimensional manner at the product and enterprise levels.

　　2021 China Medicine New innovative Force award scene

This award is a recognition of the progressiveness, innovation ability, R&D investment and enterprise competitiveness of Dongfang Baitai in the field of biopharmaceuticals. Dongfang Baitai can continue to thrive on the increasingly competitive industry track, adhere to the belief of "gathering bio pharmaceutical power and creating a healthy life for human beings", steadfastly maintain its original intention and remember its mission.

Awarding site of China's pharmaceutical innovation force in 2021

About Dongfang Baitai

Founded in 2011, Dongfang Baitai is an internationally leading innovative antibody R&D and production bio pharmaceutical company. It has more than 20 R&D pipelines. Six of them are in clinical stage. The treatment field covers diabetes, tumor, autoimmune, ophthalmology, respiratory and other diseases. The company has the first humanized antibody technology platform in China and the largest single scale antibody perfusion industrialization system in the world. The company always insists on taking innovation as the source power of enterprise development and pays attention to industrial transformation. Its new large-scale antibody industrial base in Beijing Yizhuang is under construction. The company is currently in the stage of guidance for listing on the Science and Technology Innovation Board.